Results 171 to 180 of about 3,015 (189)

A Narrative Review on Biochemical Markers and Emerging Treatments in Prodromal Synucleinopathies. [PDF]

Clin Pract
Rissardo JP, Caprara ALF.
europepmc   +1 more source

Prevalence Estimates of Cytochrome P450 Phenoconversion in Youth Receiving Pharmacotherapy for Mental Health Conditions. [PDF]

Clin Pharmacol Ther
Gerlach S, Maruf AA, Shaheen SM, McCloud R, Heintz M, McAusland L, Arnold PD, Bousman CA.   +7 more
europepmc   +1 more source

The Many Faces of REM Sleep Behavior Disorder. Providing Evidence for a New Lexicon. [PDF]

Eur J Neurol
Arnaldi D, Mattioli P, Orso B, Massa F, Pardini M, Morbelli S, Nobili F, Figorilli M, Casaglia E, Mulas M, Terzaghi M, Capriglia E, Malomo G, Solbiati M, Antelmi E, Pizza F, Biscarini F, Puligheddu M, Plazzi G.   +18 more
europepmc   +1 more source

Clinical characteristics and phenoconversion in isolated REM sleep behavior disorder: a prospective single-center study in Korea, compared with Montreal cohort. [PDF]

J Clin Sleep Med
Byun JI, Sunwoo JS, Shin YW, Shin JW, Kim TJ, Jun JS, Shin JH, Kim HJ, Montplaisir J, Gagnon JF, Pelletier A, Delva A, Postuma RB, Jung KY.   +13 more
europepmc   +1 more source

Validation of RBDtector: An Open-Source Automated Software for Scoring REM Sleep Without Atonia. [PDF]

J Sleep Res
Joza S, Pelletier A, Gagnon JF, Montplaisir JY, Bertram D, Bozek K, Postuma RB, Sommerauer M.   +7 more
europepmc   +1 more source

Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease. [PDF]

NPJ Parkinsons Dis
Hiraga K, Hattori M, Tamakoshi D, Satake Y, Fukushima T, Saito Y, Uematsu T, Tsuboi T, Sato M, Yokoi K, Suzuki K, Arahata Y, Ueki Y, Kinoshita F, Matsuda H, Murata A, Yamamoto M, Wakai M, Matsukawa N, Washimi Y, Katsuno M.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CYP2D6 pharmacogenetics and phenoconversion in personalized medicine

Expert Opinion on Drug Metabolism & Toxicology, 2022
CYP2D6 contributes to the metabolism of approximately 20-25% of drugs. However, CYP2D6 is highly polymorphic and different alleles can lead to impacts ranging from null to increase in activity. Moreover, there are commonly used drugs that potently inhibit the CYP2D6, thus causing 'phenoconversion' which can convert the genotypic normal metabolizer into
Noor A, Nahid, Julie A, Johnson
openaire   +2 more sources

Phenocopy and Phenoconversion: Do they Complicate Association Studies?

Pharmacogenomics, 2012
Current pharmacogenetic focus on genotype A number of clinically relevant drug metabo­ lizing enzymes (DMEs) are expressed poly­ morphically in the population, giving rise to at least three distinct genotypes; extensive metabolizers (EMs), poor metabolizers (PMs) and intermediate metabolizers.
Rashmi R, Shah, Robert L, Smith
openaire   +2 more sources